Mirum and Incyte Announce FOP Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Results: At ENDO 2026, Mirum and Incyte presented data showing that zilurgisertib significantly reduced new HO lesions by 81% in FOP patients over 24 weeks, indicating its potential as a new treatment option for this rare disease.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted it Priority Review, with a target action date of September 26, 2026, which could expedite its market entry to address urgent patient needs in the FOP community.
- Study Design and Findings: The PROGRESS study's first cohort included 63 patients, revealing significant reductions in HO lesion volume during the 24-week double-blind period, with no new lesions observed during the open-label extension, suggesting sustained efficacy.
- Safety Profile: Zilurgisertib demonstrated good tolerability during the 24-week study, with most adverse events being mild or moderate, and no treatment discontinuations, highlighting its safety and feasibility for clinical use.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to fall
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 107.830
Low
73.00
Averages
100.31
High
125.00
Current: 107.830
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirum and Incyte Announce New Progress in FOP Treatment
- Clinical Trial Results: At the ENDO 2026 conference, Mirum and Incyte presented results from Cohort 1 of the PROGRESS study, showing an 81% reduction in new heterotopic ossification lesions in patients treated with zilurgisertib, indicating significant efficacy in treating FOP.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted Priority Review, with a decision expected by September 26, 2026, which could provide urgently needed treatment options for FOP patients and potentially reshape the market landscape.
- Patient Data Analysis: During the 24-week double-blind period, patients receiving zilurgisertib had significantly fewer new lesions compared to the placebo group, and no new lesions were observed during the 48-week open-label extension, demonstrating sustained treatment effects and enhancing the drug's market potential.
- Safety Assessment: The study indicated that zilurgisertib was well-tolerated during the 24-week controlled period, with most adverse events being mild or moderate and no treatment discontinuations, paving the way for future commercialization and boosting investor confidence.
See More
Mirum and Incyte Announce FOP Study Results
- Clinical Trial Results: At ENDO 2026, Mirum and Incyte presented data showing that zilurgisertib significantly reduced new HO lesions by 81% in FOP patients over 24 weeks, indicating its potential as a new treatment option for this rare disease.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted it Priority Review, with a target action date of September 26, 2026, which could expedite its market entry to address urgent patient needs in the FOP community.
- Study Design and Findings: The PROGRESS study's first cohort included 63 patients, revealing significant reductions in HO lesion volume during the 24-week double-blind period, with no new lesions observed during the open-label extension, suggesting sustained efficacy.
- Safety Profile: Zilurgisertib demonstrated good tolerability during the 24-week study, with most adverse events being mild or moderate, and no treatment discontinuations, highlighting its safety and feasibility for clinical use.
See More
INCA033989 Shows Promising Clinical Benefits in Myelofibrosis and Essential Thrombocythemia
- Significant Clinical Efficacy: INCA033989 achieved spleen volume reductions of 55% and 39% in myelofibrosis (MF) patients, with notable improvements in symptoms and anemia, indicating its potential both as a monotherapy and in combination with ruxolitinib.
- High Rapid Response Rates: In essential thrombocythemia (ET) patients, 87% achieved a hematologic response, including 70% complete responses, with a median time to response of only 2 weeks, demonstrating the drug's rapid efficacy and durability.
- Consistent Molecular Activity: INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency in most evaluable patients, with reductions correlating with clinical responses, supporting its potential for disease modification.
- Favorable Safety Profile: The drug exhibited a manageable safety profile, with 84% of MF and ET patients remaining on treatment at the data cutoff, and no dose-limiting toxicities observed, indicating good tolerability.
See More
frontMIND Study Shows Tafa-Len-R-CHOP Significantly Improves Survival Rates
- Significant Survival Improvement: The frontMIND study results indicate that the Tafa-Len-R-CHOP treatment group achieved an 8.2% increase in progression-free survival (PFS), reaching 71.1% at two years compared to 62.9% for R-CHOP, highlighting the new therapy's substantial clinical significance for high-risk DLBCL patients.
- Risk Reduction: Tafa-Len-R-CHOP demonstrated a 25% reduction in the risk of disease progression or death compared to R-CHOP (HR 0.75), providing new hope for high-risk patients and potentially changing the current treatment standards.
- Good Safety Profile: Although the incidence of adverse events was slightly higher in the Tafa-Len-R-CHOP group, the overall safety was consistent with expectations, and treatment discontinuation rates were similar (5.2% vs 5.4%), indicating the therapy's feasibility in clinical applications.
- Global Regulatory Support: The frontMIND data will support global regulatory applications for Tafa-Len-R-CHOP, further advancing its potential as a standard treatment option for high-risk DLBCL, addressing the urgent market need for new therapies.
See More
Incyte Acquires Vega Therapeutics for $1.25 Billion
- Acquisition Agreement: Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion, with total potential consideration reaching $2 billion contingent on sales milestones, indicating Incyte's strategic intent to expand its hematology portfolio.
- New Drug Addition: The acquisition will add VGA039, a novel monoclonal antibody, to Incyte's hematology portfolio, which has the potential to treat various bleeding disorders, particularly all types of von Willebrand disease, thereby enhancing its competitive position in the market.
- Clinical Advancement: VGA039 is currently in a Phase 3 study designed to assess the safety and efficacy of subcutaneous administration for bleeding prophylaxis in patients with all types of von Willebrand disease, having received multiple FDA designations including fast track and breakthrough therapy, indicating a promising development outlook.
- Strategic Fit: Incyte CEO Bill Meury stated that VGA039 aligns with the company's strategy to build a top-tier growth company for the future, as it is a first-in-class Phase 3 asset with compelling early data and a manageable development path, expected to become a significant growth driver in its core therapeutic area of hematology.
See More
Incyte Nears $2 Billion Acquisition of Star Therapeutics
- Acquisition Overview: Incyte Corp. is nearing a $2 billion acquisition of Star Therapeutics, with approximately $1.25 billion in upfront cash and an additional $750 million tied to future performance, expected to be announced on Monday, reflecting a trend among midsized drugmakers to enhance their product pipelines through acquisitions.
- Therapeutic Potential: This acquisition will provide Incyte access to Star's lead experimental treatment VGA039 for von Willebrand disease, the most common inherited bleeding disorder, which is in late-stage clinical testing and has received Fast Track designation from the FDA, potentially accelerating the convenience of treatment options for patients.
- Market Opportunity: While around 35,000 patients have been treated for von Willebrand disease at U.S. hemophilia centers in recent years, industry analysts believe the potential patient population is significantly larger, indicating a substantial market opportunity, with Incyte's expertise in blood disorders aiding in commercialization efforts.
- CEO Strategic Direction: This transaction marks the first major deal under CEO Bill Meury, who has emphasized acquisitions as a strategy to offset future revenue pressures from the expected 2028 patent expiration of the company's top-selling drug Jakafi, reflecting a broader trend of consolidation in the biotechnology sector.
See More
Mirum and Incyte Announce New Progress in FOP Treatment
- Clinical Trial Results: At the ENDO 2026 conference, Mirum and Incyte presented results from Cohort 1 of the PROGRESS study, showing an 81% reduction in new heterotopic ossification lesions in patients treated with zilurgisertib, indicating significant efficacy in treating FOP.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted Priority Review, with a decision expected by September 26, 2026, which could provide urgently needed treatment options for FOP patients and potentially reshape the market landscape.
- Patient Data Analysis: During the 24-week double-blind period, patients receiving zilurgisertib had significantly fewer new lesions compared to the placebo group, and no new lesions were observed during the 48-week open-label extension, demonstrating sustained treatment effects and enhancing the drug's market potential.
- Safety Assessment: The study indicated that zilurgisertib was well-tolerated during the 24-week controlled period, with most adverse events being mild or moderate and no treatment discontinuations, paving the way for future commercialization and boosting investor confidence.
See More
Mirum and Incyte Announce FOP Study Results
- Clinical Trial Results: At ENDO 2026, Mirum and Incyte presented data showing that zilurgisertib significantly reduced new HO lesions by 81% in FOP patients over 24 weeks, indicating its potential as a new treatment option for this rare disease.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for zilurgisertib and granted it Priority Review, with a target action date of September 26, 2026, which could expedite its market entry to address urgent patient needs in the FOP community.
- Study Design and Findings: The PROGRESS study's first cohort included 63 patients, revealing significant reductions in HO lesion volume during the 24-week double-blind period, with no new lesions observed during the open-label extension, suggesting sustained efficacy.
- Safety Profile: Zilurgisertib demonstrated good tolerability during the 24-week study, with most adverse events being mild or moderate, and no treatment discontinuations, highlighting its safety and feasibility for clinical use.
See More
INCA033989 Shows Promising Clinical Benefits in Myelofibrosis and Essential Thrombocythemia
- Significant Clinical Efficacy: INCA033989 achieved spleen volume reductions of 55% and 39% in myelofibrosis (MF) patients, with notable improvements in symptoms and anemia, indicating its potential both as a monotherapy and in combination with ruxolitinib.
- High Rapid Response Rates: In essential thrombocythemia (ET) patients, 87% achieved a hematologic response, including 70% complete responses, with a median time to response of only 2 weeks, demonstrating the drug's rapid efficacy and durability.
- Consistent Molecular Activity: INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency in most evaluable patients, with reductions correlating with clinical responses, supporting its potential for disease modification.
- Favorable Safety Profile: The drug exhibited a manageable safety profile, with 84% of MF and ET patients remaining on treatment at the data cutoff, and no dose-limiting toxicities observed, indicating good tolerability.
See More
frontMIND Study Shows Tafa-Len-R-CHOP Significantly Improves Survival Rates
- Significant Survival Improvement: The frontMIND study results indicate that the Tafa-Len-R-CHOP treatment group achieved an 8.2% increase in progression-free survival (PFS), reaching 71.1% at two years compared to 62.9% for R-CHOP, highlighting the new therapy's substantial clinical significance for high-risk DLBCL patients.
- Risk Reduction: Tafa-Len-R-CHOP demonstrated a 25% reduction in the risk of disease progression or death compared to R-CHOP (HR 0.75), providing new hope for high-risk patients and potentially changing the current treatment standards.
- Good Safety Profile: Although the incidence of adverse events was slightly higher in the Tafa-Len-R-CHOP group, the overall safety was consistent with expectations, and treatment discontinuation rates were similar (5.2% vs 5.4%), indicating the therapy's feasibility in clinical applications.
- Global Regulatory Support: The frontMIND data will support global regulatory applications for Tafa-Len-R-CHOP, further advancing its potential as a standard treatment option for high-risk DLBCL, addressing the urgent market need for new therapies.
See More
Incyte Acquires Vega Therapeutics for $1.25 Billion
- Acquisition Agreement: Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion, with total potential consideration reaching $2 billion contingent on sales milestones, indicating Incyte's strategic intent to expand its hematology portfolio.
- New Drug Addition: The acquisition will add VGA039, a novel monoclonal antibody, to Incyte's hematology portfolio, which has the potential to treat various bleeding disorders, particularly all types of von Willebrand disease, thereby enhancing its competitive position in the market.
- Clinical Advancement: VGA039 is currently in a Phase 3 study designed to assess the safety and efficacy of subcutaneous administration for bleeding prophylaxis in patients with all types of von Willebrand disease, having received multiple FDA designations including fast track and breakthrough therapy, indicating a promising development outlook.
- Strategic Fit: Incyte CEO Bill Meury stated that VGA039 aligns with the company's strategy to build a top-tier growth company for the future, as it is a first-in-class Phase 3 asset with compelling early data and a manageable development path, expected to become a significant growth driver in its core therapeutic area of hematology.
See More
Incyte Nears $2 Billion Acquisition of Star Therapeutics
- Acquisition Overview: Incyte Corp. is nearing a $2 billion acquisition of Star Therapeutics, with approximately $1.25 billion in upfront cash and an additional $750 million tied to future performance, expected to be announced on Monday, reflecting a trend among midsized drugmakers to enhance their product pipelines through acquisitions.
- Therapeutic Potential: This acquisition will provide Incyte access to Star's lead experimental treatment VGA039 for von Willebrand disease, the most common inherited bleeding disorder, which is in late-stage clinical testing and has received Fast Track designation from the FDA, potentially accelerating the convenience of treatment options for patients.
- Market Opportunity: While around 35,000 patients have been treated for von Willebrand disease at U.S. hemophilia centers in recent years, industry analysts believe the potential patient population is significantly larger, indicating a substantial market opportunity, with Incyte's expertise in blood disorders aiding in commercialization efforts.
- CEO Strategic Direction: This transaction marks the first major deal under CEO Bill Meury, who has emphasized acquisitions as a strategy to offset future revenue pressures from the expected 2028 patent expiration of the company's top-selling drug Jakafi, reflecting a broader trend of consolidation in the biotechnology sector.
See More
